Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
3.940
-0.130 (-3.19%)
Aug 10, 2026, 4:00 PM EDT - Market closed
Kalaris Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 34.43 | 98.05 | 1.64 | 90.12 | 106.09 | 201.66 |
Short-Term Investments | 62.79 | 19.93 | - | 93.82 | 127.7 | 46.46 |
Cash & Short-Term Investments | 97.22 | 117.98 | 1.64 | 183.94 | 233.8 | 248.12 |
Cash Growth | -3.71% | 7098.41% | -99.11% | -21.32% | -5.77% | -30.37% |
Other Receivables | - | - | - | 0.21 | 0.16 | 0.05 |
Total Trade Receivables | - | - | - | 0.21 | 0.16 | 0.05 |
Other Current Assets | 1.25 | 0.83 | 0.97 | 3.49 | 9.1 | 5.18 |
Total Current Assets | 98.47 | 118.81 | 2.61 | 187.64 | 243.05 | 253.35 |
Net Property, Plant & Equipment | 1.43 | 1.48 | - | 2.19 | 32.56 | 31.29 |
Long-Term Investments | 7.65 | - | - | - | - | - |
Other Long-Term Assets | 2.25 | 1.45 | 0.41 | 0.97 | 1.46 | 1.95 |
Total Assets | 109.81 | 121.74 | 6.16 | 190.8 | 277.08 | 286.59 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.91 | 1.28 | 1.56 | 6.76 | 3 | 8.36 |
Accrued Expenses | - | - | - | 10.09 | 13.99 | 20.15 |
Short-Term Debt | - | - | 19.54 | - | - | - |
Current Portion of Leases | 0.32 | 0.32 | - | 10.78 | 7.17 | 6.59 |
Other Current Liabilities | - | - | 1.41 | 0.74 | 0.18 | 2.75 |
Total Current Liabilities | 8.08 | 9.71 | 24.7 | 28.37 | 24.34 | 37.85 |
Long-Term Debt | 32.08 | 32.08 | 32.08 | - | - | - |
Long-Term Leases | 1.09 | 1.13 | - | 16.65 | 28.22 | 23.48 |
Total Long-Term Liabilities | 33.17 | 33.21 | 32.08 | 16.65 | 28.22 | 23.48 |
Total Liabilities | 41.25 | 42.92 | 56.78 | 45.02 | 52.56 | 61.33 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | - | - | 0.01 | 0.01 |
Additional Paid-in Capital | 239.46 | 238.81 | 19.95 | 802.04 | 690.75 | 522.48 |
Accumulated Other Comprehensive Income | -0.05 | 0.01 | - | -0.06 | -0.47 | -0.16 |
Retained Earnings | -170.86 | -160 | -116.56 | -656.19 | -465.78 | -297.07 |
Total Common Shareholders' Equity | 68.56 | 78.81 | -96.62 | 145.78 | 224.52 | 225.27 |
Minority Interest | - | - | 46 | - | - | - |
Shareholders' Equity | 68.56 | 78.81 | -50.62 | 145.78 | 224.52 | 225.27 |
Total Liabilities & Equity | 109.81 | 121.74 | 6.16 | 190.8 | 277.08 | 286.59 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 33.49 | 33.52 | 51.62 | 27.43 | 35.39 | 30.07 |
Net Cash (Debt) | 63.73 | 84.46 | -49.98 | 156.51 | 198.41 | 218.05 |
Net Cash Growth | -7.49% | - | - | -21.12% | -9.01% | -37.27% |
Net Cash Per Share | 3.16 | 5.53 | -3.27 | 34.59 | 59.53 | 79.88 |
Book Value | 68.56 | 78.81 | -96.62 | 145.78 | 224.52 | 225.27 |
Book Value Per Share | 3.40 | 5.16 | -6.33 | 32.22 | 67.37 | 82.53 |
Tangible Book Value | 68.56 | 78.81 | -96.62 | 145.78 | 224.52 | 225.27 |
Tangible Book Value Per Share | 3.40 | 5.16 | -6.33 | 32.22 | 67.37 | 82.53 |